Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIRSNYSE:CORBFNASDAQ:OPGNNASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIRSAirSculpt Technologies$2.24+6.2%$2.76$1.53▼$9.20$131.21M1.94162,145 shs285,913 shsCORBFGlobal Cord Blood$1.05$0.92$0.25▼$2.00$127.63M-0.64174,991 shsN/AOPGNOpGen$4.99+0.4%$2.88$0.53▼$5.30$41.70M-1.6110,177 shs3,073 shsXGNExagen$6.88+3.5%$4.09$1.32▼$6.95$123.14M1.4691,068 shs323,036 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIRSAirSculpt Technologies+7.65%+24.12%-7.86%-55.67%-62.39%CORBFGlobal Cord Blood0.00%+10.53%+31.25%+3.96%-16.00%OPGNOpGen+2.94%+18.31%+23.68%+358.88%-4.64%XGNExagen+7.09%+50.11%+73.18%+63.79%+370.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIRSAirSculpt Technologies1.5937 of 5 stars3.01.00.00.01.93.30.0CORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/AXGNExagen3.5613 of 5 stars1.53.00.04.53.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIRSAirSculpt Technologies 2.00Hold$3.7567.41% UpsideCORBFGlobal Cord Blood 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/AXGNExagen 3.00Buy$7.509.01% UpsideCurrent Analyst Ratings BreakdownLatest OPGN, CORBF, AIRS, and XGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025AIRSAirSculpt TechnologiesLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$6.50 ➝ $2.503/12/2025XGNExagenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIRSAirSculpt Technologies$180.35M0.73$0.09 per share25.15$1.46 per share1.53CORBFGlobal Cord Blood$196.12M0.65$0.75 per share1.40N/A∞OPGNOpGen$2.67M15.60N/AN/A($11.55) per share-0.43XGNExagen$55.64M2.21N/AN/A$1.33 per share5.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIRSAirSculpt Technologies-$4.48M-$0.15N/A∞N/A-4.13%2.22%0.90%5/2/2025 (Estimated)CORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/AOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%6/2/2025 (Estimated)XGNExagen-$23.69M-$0.83N/AN/AN/A-30.36%-92.58%-33.74%5/12/2025 (Estimated)Latest OPGN, CORBF, AIRS, and XGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025XGNExagen-$0.20N/AN/AN/A$14.55 millionN/A5/2/2025Q1 2025AIRSAirSculpt Technologies-$0.03N/AN/AN/A$40.25 millionN/A3/14/2025Q4 2024AIRSAirSculpt Technologies-$0.03-$0.08-$0.05-$0.09$38.99 million$39.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIRSAirSculpt TechnologiesN/AN/AN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIRSAirSculpt Technologies0.800.510.51CORBFGlobal Cord BloodN/AN/AN/AOPGNOpGenN/A5.455.45XGNExagen1.544.054.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIRSAirSculpt Technologies91.54%CORBFGlobal Cord BloodN/AOPGNOpGen2.68%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipAIRSAirSculpt Technologies76.58%CORBFGlobal Cord Blood0.50%OPGNOpGen43.80%XGNExagen26.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIRSAirSculpt Technologies24058.58 million12.56 millionOptionableCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableOPGNOpGen1008.36 million4.70 millionNot OptionableXGNExagen22017.90 million13.03 millionOptionableOPGN, CORBF, AIRS, and XGN HeadlinesRecent News About These CompaniesPerceptive Advisors Enters $75MM Term Loan Facility with ExagenApril 29 at 1:17 PM | abladvisor.comExagen to Raise Up to $75M in Secured Credit FacilityApril 29 at 3:15 AM | 360dx.comExagen Inc. Announces Senior Secured Credit Facility with Perceptive AdvisorsApril 28 at 9:00 AM | globenewswire.comExagen: Buy An Undervalued Diagnostics Developer That Is On The Path To ProfitabilityApril 26 at 4:05 AM | seekingalpha.comInstitutional investors control 30% of Exagen Inc. (NASDAQ:XGN) and were rewarded last week after stock increased 30%April 25, 2025 | finance.yahoo.comExagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025April 21, 2025 | globenewswire.comExagen Inc. (NASDAQ:XGN) Shares Sold by Wasatch Advisors LPApril 20, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Short Interest UpdateApril 16, 2025 | marketbeat.comShort Interest in Exagen Inc. (NASDAQ:XGN) Drops By 23.5%March 31, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?March 14, 2025 | finance.yahoo.comExagen Full Year 2024 Earnings: EPS Beats ExpectationsMarch 12, 2025 | uk.finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comExagen (XGN) Gets a Buy from Canaccord GenuityMarch 12, 2025 | markets.businessinsider.comExagen Inc. Reports Record Revenue and Positive OutlookMarch 12, 2025 | tipranks.comExagen reports Q4 EPS (20c), consensus (24c)March 12, 2025 | markets.businessinsider.comExagen Inc. Reports Record 2024 Financial ResultsMarch 12, 2025 | tipranks.comExagen Inc. (XGN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comExagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business HighlightsMarch 11, 2025 | globenewswire.comInvestors in Exagen (NASDAQ:XGN) have unfortunately lost 84% over the last five yearsMarch 2, 2025 | finance.yahoo.comExagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025February 25, 2025 | globenewswire.comExagen granted planning consent for 34MWp solar and 75MW BESS projectFebruary 13, 2025 | solarpowerportal.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatCan NIO Overcome U.S.-China Tariff Headwinds?By Gabriel Osorio-Mazilli | April 8, 2025View Can NIO Overcome U.S.-China Tariff Headwinds?OPGN, CORBF, AIRS, and XGN Company DescriptionsAirSculpt Technologies NASDAQ:AIRS$2.24 +0.13 (+6.16%) Closing price 04:00 PM EasternExtended Trading$2.25 +0.01 (+0.45%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. The company's body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.Global Cord Blood NYSE:CORBF$1.05 0.00 (0.00%) As of 04/28/2025Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.OpGen NASDAQ:OPGN$4.99 +0.02 (+0.40%) As of 03:49 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Exagen NASDAQ:XGN$6.88 +0.23 (+3.46%) Closing price 04:00 PM EasternExtended Trading$6.94 +0.06 (+0.86%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
